Gallagher Fiduciary Advisors LLC Buys Shares of 45,248 AngioDynamics, Inc. $ANGO

by · The Markets Daily

Gallagher Fiduciary Advisors LLC purchased a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 45,248 shares of the medical instruments supplier’s stock, valued at approximately $589,000. Gallagher Fiduciary Advisors LLC owned approximately 0.11% of AngioDynamics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. BlackRock Inc. purchased a new position in AngioDynamics during the second quarter valued at approximately $49,480,000. Kotler Kevin purchased a new position in shares of AngioDynamics during the 4th quarter valued at $21,997,000. Weber Capital Management LLC ADV acquired a new position in shares of AngioDynamics in the second quarter worth $17,649,392,000. Paradigm Capital Management Inc. NY acquired a new stake in AngioDynamics during the second quarter valued at $8,732,000. Finally, UBS Group AG grew its stake in AngioDynamics by 83.6% in the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after purchasing an additional 501,881 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Trading Up 1.1%

Shares of AngioDynamics stock opened at $15.95 on Wednesday. The firm has a fifty day simple moving average of $14.11 and a 200-day simple moving average of $12.14. The stock has a market capitalization of $659.21 million, a price-to-earnings ratio of -18.33 and a beta of 0.33. AngioDynamics, Inc. has a 1-year low of $9.39 and a 1-year high of $16.29.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts predict that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity Group boosted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. HC Wainwright raised their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Hold” and a consensus price target of $19.50.

Read Our Latest Report on ANGO

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.00% of the company’s stock.

AngioDynamics Profile

(Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

Recommended Stories